CRG

Calyxo specializes in the development of a vacuum-assisted kidney stone retrieval device aimed at enhancing the efficiency and effectiveness of urological procedures. This innovative device allows for the extraction of multiple kidney stone fragments in a single insertion, significantly reducing the time required for the procedure. By enabling doctors to achieve a high stone-free outcome quickly and intuitively, Calyxo's technology enhances clinical results and improves patient care.

NavaDerm Partners, LLC is a practice management company that specializes in supporting dermatology healthcare centers offering a range of medical, surgical, and cosmetic services. Founded in 2018 and headquartered in New York, the company operates centers in various locations, including Millburn, Tenafly, the Bronx, and New York City. NavaDerm's facilities provide treatments for skin conditions such as acne, psoriasis, and skin cancers, as well as cosmetic procedures like laser treatments and body contouring. In addition to patient care, NavaDerm offers essential business services to dermatologists, including revenue cycle management, accounting, human resources, and IT support. This comprehensive approach allows physicians to concentrate on delivering quality care while enhancing their practices' operational efficiency and reputation.

Treace Medical Concepts is a medical device company based in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of innovative solutions for foot and ankle surgery. Founded in 2014, the company focuses on enhancing surgical practices, particularly in the treatment of bunion deformities through its patented Lapiplasty 3D Bunion Correction procedure, which aims to address the root causes of bunions and facilitate quicker recovery for patients. Additionally, Treace offers the ProHarvester, a percutaneous autograft extraction system that allows surgeons to obtain autograft bone and marrow via a minimally invasive approach. Operating within the $1.1 billion U.S. market for foot and ankle surgical products, Treace Medical Concepts is committed to improving patient outcomes while also striving to provide a rewarding experience for its employees and value for its shareholders.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

EyePoint Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of eye diseases, primarily in the United States and Europe. The company offers several FDA-approved products, including ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, DEXYCU for post-operative ocular inflammation, and Retisert for posterior segment uveitis. EyePoint is also advancing its pipeline with EYP-1901, a bioerodible implant targeting wet age-related macular degeneration and related conditions, as well as YUTIQ50 for uveitis. The company utilizes its proprietary Durasert and Verisome technology platforms to create sustained-release drug delivery systems. EyePoint has established strategic collaborations with various organizations and engages in a commercial alliance for the promotion of its products. Founded in 1987 and headquartered in Watertown, Massachusetts, EyePoint was previously known as pSivida Corp.

Mid-Atlantic Dental Partners is a regional dental support organization that focuses on enhancing the delivery of dental care. Founded on the principle of a collaborative partnership among patients, dentists, and support organizations, it aims to allow dental professionals to concentrate on patient care by managing non-clinical activities. These services encompass billing, collections, scheduling, clinical data analytics, group purchasing, marketing, and recruitment of dental staff. The organization is dedicated to maintaining clinical autonomy for dentists while improving the overall lifestyle of its dental partners and their teams.

HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company is known for its Transoral Incisionless Fundoplication (TIF®) procedure, which provides a minimally invasive alternative to traditional surgical methods by allowing treatment without external incisions. Key products include the EsophyX technology, which facilitates transoral reconstructive surgery, and the SerosaFuse Fasteners, designed for secure tissue attachment. Additionally, EndoGastric Solutions offers training courses for surgeons and a range of consultative support services. Founded in 2002 and headquartered in Redmond, Washington, the company also has an office in San Mateo, California.

Fast Pace Urgent Care is dedicated to providing primary, walk-in and urgent care to the communities they serve. They provide treatments for a wide range of illnesses, injuries, and common conditions, as well as provide a variety of wellness, diagnostic and screening services.

Synergy Pharmaceuticals Inc., based in New York with laboratories in Doylestown, PA, is a biopharmaceutical company dedicated to the research and development of innovative therapies for gastrointestinal conditions. The company primarily focuses on chronic idiopathic constipation, irritable bowel syndrome with constipation, and other challenging GI disorders. Its leading product, plecanatide, is a once-daily tablet designed to treat chronic idiopathic constipation and irritable bowel syndrome. Additionally, Synergy is developing dolcanatide, which targets inflammatory bowel disease by enhancing digestive processes. Both plecanatide and dolcanatide are proprietary analogs of the natural human gastrointestinal hormone uroguanylin and belong to a new class of guanylate cyclase-C (GC-C) agonists, reflecting the company’s commitment to addressing unmet medical needs in the gastrointestinal space.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that focuses on developing innovative solutions for carotid artery disease. The company specializes in transcarotid artery revascularization (TCAR), a minimally invasive approach designed to reduce the risk of stroke during surgical interventions. Its product lineup includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery and allows for temporary blood flow reversal to protect the brain. Additionally, the ENROUTE Transcarotid Stent System is a self-expanding stent backed by clinical evidence supporting its safety outcomes. Other offerings include the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire for guiding interventional devices. Founded in 2007, Silk Road Medical aims to improve patient care through collaboration with vascular specialists and ongoing innovation in vascular therapies.

Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.

Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.

Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.

Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.

Viveve is a women's sexual health company that develops non-surgical treatment for women's sexual health. It focuses on developing a Viveve procedure, a non-surgical treatment for women who have experienced vaginal looseness and loss of physical sensation that is common to women after vaginal childbirth. The company’s Viveve System is a radiofrequency device that uses low levels of energy to restore collagen fibers overstretched and damaged during vaginal childbirth. Viveve, Inc. was formerly known as TiVaMed, Inc. and changed its name to Viveve, Inc. in November 2009. The company was founded in 2005 and is based in Palo Alto, California.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on developing and marketing pharmaceutical products for pain management and addiction medicine in the United States and internationally. The company utilizes its patented BioErodible MucoAdhesive (BEMA) technology, which consists of a small erodible polymer film designed for application to the buccal mucosa, to create effective drug delivery systems. Its product portfolio includes BELBUCA, a buprenorphine buccal film for chronic pain management; BUNAVAIL, a combination buccal film of buprenorphine and naloxone for treating opioid dependence; and ONSOLIS, a fentanyl buccal film for managing breakthrough pain in cancer patients. Additionally, BioDelivery Sciences offers Symproic, a medication for opioid-induced constipation in adults with chronic non-cancer pain. Founded in 1997 and headquartered in Raleigh, North Carolina, the company aims to address significant unmet medical needs in the therapeutic areas it serves.

Endoceutics is a private biopharmaceutical company focused on women's health, particularly in the areas of hormone-sensitive cancer prevention and treatment. The company aims to develop non-estrogen-based therapies for various menopausal symptoms, including sexual dysfunction, hot flushes, osteoporosis, muscle loss, and type 2 diabetes. Since the FDA approval of its product Intrarosa for treating dyspareunia in 2016, Endoceutics has expanded its pipeline to include hormonal therapies targeting breast, uterine, and prostate cancers, as well as conditions like male hypogonadism and endometriosis. The company is advancing five product candidates in Phase III trials and two in Phase I/II trials, addressing significant market needs. Endoceutics holds exclusive worldwide rights to its related patents, technology, and know-how, positioning itself to offer effective and physiological treatments for menopausal issues and hormone-sensitive conditions.

Intrinsic Therapeutics, Inc. develops and manufactures medical devices aimed at treating lumbar disc herniations, primarily under the trade name Barricaid. The company specializes in creating anular prostheses for partial replacement following discectomy surgery, as well as an anular closure device designed to prevent reherniations in patients with anular defects. Barricaid enables the reconstruction of weakened and ruptured spinal tissues, addressing issues related to sciatica and low back pain. Intrinsic Therapeutics serves both surgeons and patients and distributes its products across various countries, including Germany, Austria, Australia, and several others in Europe and Latin America. Founded in 2000 and based in Woburn, Massachusetts, the company also maintains offices in Oirschot, The Netherlands, and Düsseldorf, Germany.

Hicuity Health is a leading provider of high-acuity telehealth services, focused on enhancing intensive care unit (ICU) programs for hospitals across the United States. The company offers tele-ICU solutions that enable hospitals to improve patient care while optimizing clinical, operational, and financial performance. Hicuity Health employs advanced telemedicine technology to analyze real-time patient data and facilitate two-way video conferencing between care teams and patients. They provide round-the-clock clinical services to nearly 100 hospitals in 27 states, leveraging U.S. board-certified intensivists and dedicated tele-care delivery centers. Additionally, Hicuity Health supports hospitals with consulting services to enhance their ICU operations. Founded in 2004 and headquartered in St. Louis, Missouri, the company operates multiple centers nationwide, including locations in Texas, California, New York, Hawaii, South Carolina, and Washington, D.C.

T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.

Omeros Corporation is a Seattle-based biopharmaceutical company engaged in the discovery, development, and commercialization of small-molecule and protein therapeutics. The company focuses on large-market and orphan indications, particularly targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. Omeros offers OMIDRIA, a product used during cataract surgery in the United States. Its clinical pipeline includes narsoplimab, a monoclonal antibody in Phase III trials for various conditions, including hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy. Other clinical programs involve treatments for opioid and nicotine addiction, as well as compulsive disorders. Preclinical efforts include developing therapies for paroxysmal nocturnal hemoglobinuria and exploring a range of G protein-coupled receptors for various disorders. Founded in 1994, Omeros is committed to addressing significant unmet medical needs through its innovative therapeutic approaches.

SOC Telemed, Inc. specializes in telemedicine technology and solutions for hospitals, health systems, and other healthcare providers across the United States. Established in 2004 and headquartered in Reston, Virginia, the company offers a technology platform called Telemed IQ, which supports a variety of telemedicine programs, including teleNeurology, telePsychiatry, and teleICU. By providing specialty consultations to acute-care hospitals, SOC Telemed enhances access to care and aims to improve patient outcomes while optimizing organizational efficiencies. The company boasts a network of experienced clinicians and has facilitated over 500,000 consultations, making it a prominent player in the telemedicine sector.

US WorldMeds is a Kentucky-based specialty pharmaceutical company focused on developing, licensing, and commercializing unique pharmaceuticals that address unmet medical needs. Founded in 2001 by CEO Paul Breckinridge Jones, the company is dedicated to creating innovative treatments primarily for conditions such as Parkinson's disease, cervical dystonia, and malignant hyperthermia. By targeting rare diseases and conditions with limited treatment options, US WorldMeds aims to enhance patient care and improve the quality of life for individuals facing these challenges. The company operates from its headquarters in Louisville and maintains satellite offices and manufacturing facilities, emphasizing its commitment to local talent and community development.

Iroko Pharmaceuticals, LLC is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing and commercializing innovative pharmaceutical products for pain management. Founded in 2007, the company markets a range of prescription pain medications, including Indocid, Aldomet, TIVORBEX, ZORVOLEX, and VIVLODEX, which are designed to address various pain management needs, particularly for patients with osteoarthritis and acute pain. Iroko utilizes proprietary technology to formulate lower-dose nonsteroidal anti-inflammatory drugs (NSAIDs), improving therapeutic options for patients. The company has established a robust distribution and sales network, extending its reach to more than 40 countries, and aims to enhance healthcare by revitalizing existing medications through new applications and geographic markets.

Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

Autonomic Technologies, Inc. is a medical device company that focuses on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. It develops ATI Neurostimulation System, a device that delivers low-level energy directly to the area of the SPG for the treatment of chronic cluster headache. The company was founded in 2007 and is based in Mountain View, California with additional offices in Germany and Switzerland.

Benvenue Medical, Inc. specializes in the design, manufacturing, and marketing of minimally invasive expandable implant systems for treating spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. The company offers products such as the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, aimed at treating various types of pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system designed for use in minimally invasive, mini-open, or open surgical procedures. Established in 2004 and headquartered in Santa Clara, California, the company serves a diverse customer base in the United States, Canada, Belgium, France, and Germany.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company is known for its Transoral Incisionless Fundoplication (TIF®) procedure, which provides a minimally invasive alternative to traditional surgical methods by allowing treatment without external incisions. Key products include the EsophyX technology, which facilitates transoral reconstructive surgery, and the SerosaFuse Fasteners, designed for secure tissue attachment. Additionally, EndoGastric Solutions offers training courses for surgeons and a range of consultative support services. Founded in 2002 and headquartered in Redmond, Washington, the company also has an office in San Mateo, California.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that focuses on developing innovative solutions for carotid artery disease. The company specializes in transcarotid artery revascularization (TCAR), a minimally invasive approach designed to reduce the risk of stroke during surgical interventions. Its product lineup includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery and allows for temporary blood flow reversal to protect the brain. Additionally, the ENROUTE Transcarotid Stent System is a self-expanding stent backed by clinical evidence supporting its safety outcomes. Other offerings include the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire for guiding interventional devices. Founded in 2007, Silk Road Medical aims to improve patient care through collaboration with vascular specialists and ongoing innovation in vascular therapies.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Avinger, Inc. is a medical device company based in Redwood City, California, that specializes in developing catheter-based technologies for treating peripheral arterial disease (PAD). Founded in 2007, the company designs and manufactures image-guided systems that assist physicians in performing minimally invasive procedures. Avinger's product lineup includes the Lightbox imaging console and the Ocelot family of catheters, which enable doctors to navigate and treat chronic total occlusions (CTOs) in arteries. Additionally, the Pantheris device provides image-guided atherectomy, allowing for precise removal of arterial plaque. Avinger's innovations aim to enhance treatment outcomes for patients with PAD, and its products are marketed primarily to interventional cardiologists, vascular surgeons, and interventional radiologists, serving both the U.S. and international markets.

ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.

Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates through two main segments: Diagnostic Substances and Therapeutic Development Programs. Central to its offerings is the Manocept platform, which targets the CD206 mannose receptor found on activated macrophages, enabling a range of diagnostic applications, including advanced imaging techniques and the delivery of therapeutic compounds. Notable products include NAV4694, a PET imaging agent for Alzheimer's disease and mild cognitive impairment, and Tc99m tilmanocept, a diagnostic substance. The company is also engaged in collaborative efforts to explore the potential of its platform with other immunotherapies. Founded in 1983 and headquartered in Dublin, Ohio, Navidea Biopharmaceuticals aims to enhance diagnostic accuracy and treatment outcomes for various serious conditions, including cancer and inflammatory diseases.

Ceterix Orthopaedics, Inc. develops novel surgical tools for arthroscopic procedures. The Ceterix technology enables surgeons to place stitches in very tight joint compartments, while protecting sensitive surrounding structures such as nerves, arteries and cartilage. This technology has applications in numerous arthroscopic procedures in knees, hips and shoulders. Ceterix was established in October 2010. The company was founded based on the inventions of Dr. Justin Saliman, an orthopaedic surgeon specializing in sports medicine. Dr. Saliman envisioned improving the outcomes of arthroscopic procedures by enabling surgeons to place suture patterns that today can be done only in open procedures, if at all. Ceterix is based in Menlo Park, California.

TearLab Corporation is an in-vitro diagnostic company based in Escondido, California, specializing in the development of lab-on-a-chip technologies for eye care. The company's flagship product, the TearLab Osmolarity System, is a proprietary platform designed for the diagnosis of dry eye disease by measuring tear film osmolarity. This system enables eye care practitioners to test for specific biomarkers using minimal tear samples at the point-of-care. The TearLab Osmolarity System includes a disposable microfluidic microchip, a hand-held device called the TearLab Pen, and a desktop unit, the TearLab Reader, which provides quantitative readings. Established in 1996, TearLab was formerly known as OccuLogix, Inc., and as of July 2020, it has transitioned to a private company.

Imaging Advantage is the leading provider of evidence-based, end-to-end technology enhanced radiology solutions to hospitals across the country. IA’s footprint includes major healthcare systems in Arizona, California, Illinois, Michigan, Ohio, Oregon and Texas, as well as other major metropolitan areas across the U.S.

Imaging Advantage is the leading provider of evidence-based, end-to-end technology enhanced radiology solutions to hospitals across the country. IA’s footprint includes major healthcare systems in Arizona, California, Illinois, Michigan, Ohio, Oregon and Texas, as well as other major metropolitan areas across the U.S.

Blue Belt Technologies is a medical device company that focuses on technology and capabilities of surgical instrumentation. They proprietary technology can improve minimally invasive techniques in orthopedics, providing physicians with consistency and accuracy through a myriad of intelligent hand-held tools. It also enables the development of more advanced solutions to patients’ problems. Blue Belt Technologies was acquired by Smith & Nephew on January 5m 2016. The company was founded in 2003 and is headquartered in Pennsylvania, USA.

Nevro Corp. is a medical device company that focuses on developing innovative solutions for patients suffering from chronic pain. Based in Redwood City, California, the company has created the Senza spinal cord stimulation (SCS) system, which is an evidence-based neuromodulation platform that includes the proprietary HF10 therapy. This therapy provides electrical impulses to alleviate pain and is controlled by patients through a remote device. Nevro's product offerings extend to the Senza II and Senza Omnia systems, which are designed for chronic pain management. The company markets its products primarily in the United States and utilizes a direct sales force, along with a network of sales agents and independent distributors, to reach its customers. Founded in 2006, Nevro aims to enhance the quality of life for individuals affected by debilitating pain through its advanced medical technologies.

Astute Medical, Inc. is a life science tools company specializing in the discovery and development of protein biomarkers for rapid diagnosis and risk assessment of acute medical conditions. Founded in 2007 and based in San Diego, California, with a location in Paris, France, the company focuses on validating prognostic biomarkers related to conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its primary product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck cartridge into a single numerical result. Astute Medical's products are marketed in the United States and Europe and aim to enhance clinical decision-making and patient outcomes. As of April 2018, Astute Medical operates as a subsidiary of bioMérieux S.A.

Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.

AFT Pharmaceuticals is a pharmaceutical company that develops, licenses, and markets a diverse range of medical products. Founded in 1997 and headquartered in Auckland, New Zealand, the company offers approximately 130 prescription and non-prescription products across various therapeutic areas, including allergy relief, eye care, pain management, and skin care, as well as dietary supplements. AFT specializes in sourcing niche prescription pharmaceuticals and actively engages in drug development activities, including clinical trials. Its product portfolio includes moisturizers, calcium supplements, pain relief tablets, and children's medications, among others. The company serves pharmacies and hospitals in Australia, New Zealand, and Southeast Asia, with additional operational offices in Kuala Lumpur and Singapore. AFT Pharmaceuticals primarily generates its revenue from the Australian market, reflecting its strong distribution capabilities in the region.

NanoString Technologies, Inc. is a provider of life science tools for translational research and molecular diagnostics on a global scale. The company specializes in the nCounter Analysis System, an automated platform for digital detection and quantification of nucleic acids. Key products include the nCounter MAX and FLEX systems, which feature an automated liquid handling component and a digital analyzer for data collection. Additionally, NanoString offers the nCounter SPRINT Profiler, nSolver Analysis Software, and custom CodeSets for tailored research needs. The company has developed various gene expression panels for cancer, autoimmune diseases, and other conditions. Furthermore, NanoString is advancing spatial genomics through its GeoMx Digital Spatial Profiler and Hyb & Seq molecular profiling systems. Collaborations with prominent organizations, including Celgene and Merck, enhance its research capabilities, particularly in developing novel protein assays for breast cancer. Founded in 2003 and headquartered in Seattle, Washington, NanoString continues to innovate in the field of molecular diagnostics and research tools.

Biodesix, Inc. is a diagnostic solutions company based in Boulder, Colorado, specializing in blood-based tests for lung cancer and other diseases. The company provides a range of diagnostic services, including the Nodify XL2 and Nodify CDT tests, which help physicians assess the risk of malignancy in patients with suspicious lung nodules. Additionally, Biodesix offers tumor profiling through its GeneStrat test and immune profiling with VeriStrat, aiding treatment decisions for advanced lung cancer. The tests are processed in a CLIA-certified laboratory, with results typically reported within 72 hours. Biodesix also engages in diagnostic research and collaborates with biopharmaceutical companies to develop companion diagnostics, enhancing the effectiveness of therapeutic agents. Founded in 2005, the company has a strong commitment to advancing personalized medicine and improving patient outcomes through innovative diagnostic solutions.

Solta Medical, Inc. specializes in designing, developing, manufacturing, and marketing energy-based medical devices focused on aesthetic applications. The company offers a range of products, including the Thermage NXT system for non-invasive skin tightening and contouring, and the Fraxel series of systems that treat various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. Their devices incorporate advanced technology with handpieces, user-friendly consoles, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and general practitioners, and distributes its products through a direct sales force and a network of international distributors. Founded in 1995 and headquartered in Hayward, California, the company was previously known as Thermage, Inc. before rebranding in 2009.

Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.

Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.

RainDance Technologies, Inc. specializes in developing genomic tools for non-invasive liquid biopsy applications, focusing on the research, early detection, and treatment of cancer and other diseases. The company offers a range of products, including the RainDrop digital polymerase chain reaction platform, which utilizes picoliter-sized droplets for the multiplex detection of various genetic materials such as DNA and RNA. Additionally, it provides the RainDrop Plus system for next-generation sequencing (NGS) amplicon enrichment and the ThunderStorm automated NGS content enrichment solution, which enhances the processing of samples and data quality. RainDance also offers targeted NGS panels like ThunderBolts, aimed at profiling cancer mutations and understanding myeloid disorders. The company serves major research institutions and laboratories globally through a network of sales representatives and distributors. Founded in 2004 and based in Billerica, Massachusetts, RainDance Technologies operates as a subsidiary of Bio-Rad Laboratories, Inc.

On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

Good Start Genetics, Inc., founded in 2007 and based in Cambridge, Massachusetts, is a molecular diagnostics company specializing in genetic screening for inherited diseases. The company aims to transform reproductive medicine by offering clinically relevant information to physicians and patients regarding genetic disorders. Its flagship product, EmbryVu, is a preimplantation genetic screening test designed to enhance in vitro fertilization by identifying suitable embryos for implantation and pregnancy. Good Start Genetics employs advanced next-generation DNA sequencing (NGS) technology, alongside other established genetic screening methods, to provide a comprehensive suite of genetic carrier screening tests through its GoodStart Select program. The company emphasizes customer care and genetic counseling, ensuring that patients receive actionable insights into known and novel genetic mutations. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic conditions. The company is known for its Ovation System, which includes a stent graft platform designed for endovascular aortic repair. Key components of the Ovation System feature an aortic body, iliac limbs, and polymer fill, which contribute to its effectiveness in treating AAA. TriVascular markets its products through direct sales in the United States and several European countries, as well as via distributors in other regions. Founded in 2007 and headquartered in Santa Rosa, California, TriVascular has been recognized for its innovative approach to addressing unmet clinical needs in aortic disease treatment. The company operates as a subsidiary of Endologix Inc.

Tandem Diabetes Care, Inc. develops medical devices for the treatment of diabetes. It offers diabetic insulin pumps for adults and children to diabetes needs, including keeping blood glucose levels within target ranges. The company focuses on insulin infusion therapy. Tandem Diabetes Care, Inc. was incorporated in 2006 and is based in San Diego, California.

Corium International, Inc. is a biopharmaceutical company specializing in the development, manufacture, and commercialization of specialty pharmaceutical products that utilize transdermal and transmucosal delivery systems. The company offers several products, including a clonidine transdermal delivery system for hypertension, fentanyl patches for chronic pain management, and Crest Whitestrips for teeth whitening. Its product pipeline features innovative therapies, such as Twirla, a hormonal contraceptive patch, and a transdermal system for severe osteoporosis. Additionally, Corium is developing transdermal systems for Alzheimer's disease, psychiatric disorders, and motion sickness. The company collaborates with various pharmaceutical partners to advance its product offerings. Established in 1995, Corium International is headquartered in Menlo Park, California, and operates with a focus on enhancing therapeutic outcomes through advanced drug delivery technologies.

Bioniche Pharma Group manufactures and markets sterile injectable pharmaceutical products.